Melanoma cell plasticity poses diagnostic challenges: a case series.
Journal
Melanoma research
ISSN: 1473-5636
Titre abrégé: Melanoma Res
Pays: England
ID NLM: 9109623
Informations de publication
Date de publication:
01 12 2022
01 12 2022
Historique:
pubmed:
21
9
2022
medline:
3
11
2022
entrez:
20
9
2022
Statut:
ppublish
Résumé
Phenotype switching is an emerging concept in melanoma research and deals with the cancer cell plasticity. In this paper, we present five cases of patients with metastatic malignant melanoma where the tumor underwent dramatic morphological and immunohistochemical changes thereby mimicking other types of malignancies. The diagnosis of melanoma in all these cases was based on the mutational profile of the tumor assessed by next-generation sequencing compared to the primary lesion or local regional lymph nodes. These cases highlight the importance of thorough diagnostic measures in patients with metastatic melanoma who show progressive disease and where basic pathological assessment shows a diagnostic discrepancy.
Identifiants
pubmed: 36125893
doi: 10.1097/CMR.0000000000000852
pii: 00008390-202212000-00005
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
428-439Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Ohsie SJ, Sarantopoulos GP, Cochran AJ, Binder SW. Immunohistochemical characteristics of melanoma. J Cutan Pathol 2008; 35:433–444.
Grzywa TM, Paskal W, Włodarski PK. Intratumor and intertumor heterogeneity in melanoma. Transl Oncol 2017; 10:956–975.
Nieto MA, Huang RY, Jackson RA, Thiery JP. EMT: 2016. Cell 2016; 166:21–45.
Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol 2019; 20:69–84.
Ribatti D, Tamma R, Annese T. Epithelial-mesenchymal transition in cancer: a historical overview. Transl Oncol 2020; 13:100773.
Yang J, Antin P, Berx G, Blanpain C, Brabletz T, Bronner M, et al. Guidelines and definitions for research on epithelial–mesenchymal transition. Nat Rev Mol Cell Biol 2020; 21:341–352.
Hoek KS, Goding CR. Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell Melanoma Res 2010; 23:746–759.
Hoek KS, Eichhoff OM, Schlegel NC, Döbbeling U, Kobert N, Schaerer L, et al. In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res 2008; 68:650–656.
Wouters J, Kalender-Atak Z, Minnoye L, Spanier KI, De Waegeneer M, Bravo González-Blas C, et al. Robust gene expression programs underlie recurrent cell states and phenotype switching in melanoma. Nat Cell Biol 2020; 22:986–998.
Rambow F, Marine JC, Goding CR. Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunities. Genes Dev 2019; 33:1295–1318.
Denecker G, Vandamme N, Akay O, Koludrovic D, Taminau J, Lemeire K, et al. Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression. Cell Death Differ 2014; 21:1250–1261.
Gallagher SJ, Bailey T, Rawson RV, Mahar AM, Thompson JF, Long GV, et al. Melanoma with osseous or chondroid differentiation: a report of eight cases including SATB2 expression and mutation analysis. Pathology 2021; 53:830–835.
Banerjee SS, Eyden B. Divergent differentiation in malignant melanomas: a review. Histopathology 2008; 52:119–129.
Eyden B, Pandit D, Banerjee SS. Malignant melanoma with neuroendocrine differentiation: clinical, histological, immunohistochemical and ultrastructural features of three cases. Histopathology 2005; 47:402–409.
Tran TAN, Linos K, de Abreu FB, Carlson JA. Undifferentiated sarcoma as intermediate step in the progression of malignant melanoma to rhabdomyosarcoma: histologic, immunohistochemical, and molecular studies of a new case of malignant melanoma with rhabdomyosarcomatous differentiation. Am J Dermatopathol 2019; 41:221–229.
McKay KM, Deavers MT, Prieto VG. Chondroid melanoma metastatic to lung and skin showing SOX-9 expression: a potential diagnostic pitfall. Int J Surg Pathol 2012; 20:169–172.
Kacerovska D, Michal M, Kutzner H, Rychnovsky J, Kazakov DV. Metastatic desmoplastic malignant melanoma associated with low-grade myofibroblastic sarcoma. Am J Dermatopathol 2009; 31:490–494.
Ul-Mulk J, Rasmussen H, Breiting L, Siim E. A case of collision tumor or transdifferentiation between malignant melanoma and leiomyosarcoma. Indian J Pathol Microbiol 2012; 55:538–539.
Agaimy A, Specht K, Stoehr R, Lorey T, Märkl B, Niedobitek G, et al. Metastatic malignant melanoma with complete loss of differentiation markers (undifferentiated/dedifferentiated melanoma): analysis of 14 patients emphasizing phenotypic plasticity and the value of molecular testing as surrogate diagnostic marker. Am J Surg Pathol 2016; 40:181–191.
Agaimy A, Stoehr R, Hornung A, Popp J, Erdmann M, Heinzerling L, Hartmann A. Dedifferentiated and undifferentiated melanomas: report of 35 new cases with literature review and proposal of diagnostic criteria. Am J Surg Pathol 2021; 45:240–254.
Fox Hanson K, Birinyi P, Walker R, Raptis C, Chernock R, Coppens J, Schwetye KE. Melanoma mimicking malignant peripheral nerve sheath tumor with spread to the cerebellopontine angle: utility of next-generation sequencing in diagnosis. Case Rep Pathol 2018; 2018:9410465.
Saleh J, Wang ML, Harms PW, Patel RM, Fullen DR. Malignant melanoma with osteosarcomatous differentiation in a lymph node metastasis. J Cutan Pathol 2018; 45:701–704
Banerjee SS, Bishop PW, Nicholson CM, Eyden BP. Malignant melanoma showing smooth muscle differentiation. J Clin Pathol 1996; 49:950–951.
Jalas JR, Vemula S, Bezrookove V, Leboit PE, Simko JP, Bastian BC. Metastatic melanoma with striking adenocarcinomatous differentiation illustrating phenotypic plasticity in melanoma. Am J Surg Pathol 2011; 35:1413–1418.
Carlson JA, Dickersin GR, Sober AJ, Barnhill RL. Desmoplastic neurotropic melanoma. A clinicopathologic analysis of 28 cases. Cancer 1995; 75:478–494.
Mao L, Dai J, Cao Y, Bai X, Sheng X, Chi Z, et al. Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway. Eur J Cancer 2021; 148:297–306.
Pedri D, Karras P, Landeloos E, Marine JC, Rambow F. Epithelial-to-mesenchymal-like transition events in melanoma. FEBS J 2022; 289:1352–1368.
Huang F, Santinon F, Flores González RE, Del Rincón SV. Melanoma plasticity: promoter of metastasis and resistance to therapy. Front Oncol 2021; 11:756001.
Massi D, Mihic-Probst D, Schadendorf D, Dummer R, Mandalà M. Dedifferentiated melanomas: morpho-phenotypic profile, genetic reprogramming and clinical implications. Cancer Treat Rev 2020; 88:102060.
Wang L, Motoi T, Khanin R, Olshen A, Mertens F, Bridge J, et al. Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data. Genes Chromosomes Cancer 2012; 51:127–139.
Cipriani NA, Letovanec I, Hornicek FJ, Mullen JT, Duan Z, Borger DR, et al. BRAF mutation in ‘sarcomas’: a method to detect de-differentiated melanomas. Histopathology 2014; 64:639–646.
Alrabadi N, Gibson N, Curless K, Cheng L, Kuhar M, Chen S, et al. Detection of driver mutations in BRAF can aid in diagnosis and early treatment of dedifferentiated metastatic melanoma. Mod Pathol 2019; 32:330–337.
Koelsche C, Wöhrer A, Jeibmann A, Schittenhelm J, Schindler G, Preusser M, et al. Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells. Acta Neuropathol 2013; 125:891–900.